These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32988633)

  • 21. Rotavirus gastroenteritis hospitalization rates and correlation with rotavirus vaccination coverage in Sicily.
    Restivo V; Caracci F; Sannasardo CE; Scarpitta F; Vella C; Ventura G; Tramuto F; Costantino C
    Acta Biomed; 2018 Oct; 89(3):437-442. PubMed ID: 30333453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.
    Patel MM; Clark AD; Glass RI; Greenberg H; Tate J; Santosham M; Sanderson CF; Steele D; Cortese M; Parashar UD
    Vaccine; 2009 May; 27(22):2916-22. PubMed ID: 19428901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Socioeconomic Impact of the Rotavirus Vaccine in Korea: Comparing the Epidemiologic and Economic Characteristics of Rotavirus Gastroenteritis Before and After the Introduction of Vaccines.
    Cho H; Lee H; Kim DS; Kim HM; Kim JH; Kim AY; Kang HY
    Pediatr Infect Dis J; 2020 May; 39(5):460-465. PubMed ID: 31990891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data, 2001-2016.
    Baker JM; Dahl RM; Cubilo J; Parashar UD; Lopman BA
    BMC Infect Dis; 2019 Feb; 19(1):186. PubMed ID: 30795739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis.
    Tafalla M; Gardovska D; Gopala K; Kozlovska L
    Hum Vaccin Immunother; 2019; 15(6):1272-1278. PubMed ID: 30335570
    [No Abstract]   [Full Text] [Related]  

  • 26. Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination.
    Clarke MF; Davidson GP; Gold MS; Marshall HS
    Vaccine; 2011 Jun; 29(29-30):4663-7. PubMed ID: 21575665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.
    Arlegui H; Nachbaur G; Praet N; Bégaud B
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa087. PubMed ID: 32296726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain.
    Orrico-Sanchez A; López-Lacort M; Pérez-Vilar S; Díez-Domingo J
    BMC Infect Dis; 2017 Apr; 17(1):267. PubMed ID: 28399824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
    Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
    Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
    Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus.
    Kõivumägi K; Toompere K; Soeorg H; Kallas E; Jõgeda EL; Huik K; ; Lutsar I
    Vaccine; 2020 Mar; 38(13):2879-2886. PubMed ID: 32067818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
    Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
    Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid impact of rotavirus vaccine introduction to the National Immunization plan in southern Israel: comparison between 2 distinct populations.
    Givon-Lavi N; Ben-Shimol S; Cohen R; Greenberg D; Dagan R
    Vaccine; 2015 Apr; 33(16):1934-40. PubMed ID: 25744226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
    Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
    PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009.
    Yen C; Tate JE; Steiner CA; Cortese MM; Patel MM; Parashar UD
    J Infect Dis; 2012 Jul; 206(1):41-8. PubMed ID: 22539812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Universal rotavirus vaccination program in Sicily: Reduction in health burden and cost despite low vaccination coverage.
    Costantino C; Restivo V; Tramuto F; Casuccio A; Vitale F
    Hum Vaccin Immunother; 2018; 14(9):2297-2302. PubMed ID: 29757707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia.
    Burnett E; Tate JE; Kirkwood CD; Nelson EAS; Santosham M; Steele AD; Parashar UD
    Expert Rev Vaccines; 2018 May; 17(5):453-460. PubMed ID: 29463143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria.
    Paulke-Korinek M; Kollaritsch H; Aberle SW; Zwazl I; Schmidle-Loss B; Vécsei A; Kundi M
    Vaccine; 2013 May; 31(24):2686-91. PubMed ID: 23597718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?
    Haber P; Chen RT; Zanardi LR; Mootrey GT; English R; Braun MM;
    Pediatrics; 2004 Apr; 113(4):e353-9. PubMed ID: 15060267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
    Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
    Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.